PharmaEngine, Inc. 4162.TWO
1H 2024 Investors' Conference
2024/07/31

Jackie Chang, Investor Relations

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future,’ or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. **Pricing and product initiatives of competitors**
2. **Legislative and regulatory developments and economic conditions**
3. **Delay or inability in obtaining regulatory approvals or bringing products to market**
4. **Fluctuations in currency exchange rates and general financial market conditions**
5. **Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products**
6. **Increased government pricing pressures**
7. **Interruptions in production**
8. **Loss of or inability to obtain adequate protection for intellectual property rights**
9. **Litigation**
10. **Loss of key executives or other employees**
11. **Adverse publicity and news coverage**

PharmaEngine cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. PharmaEngine undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that PharmaEngine ’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of PharmaEngine, Inc.

AGENDA

1. 1H 2024 Operational Highlights
2. 1H 2024 Operational Overview
3. Research and Development
   - ONIVYDE®
   - Pipeline
4. Vision for 2024
5. Q&A

1H 2024 Operational Highlights: Sustainable Growth and Enhanced Pipeline

COMMERCIAL

ONIVYDE®
Indication expansion

In 2024, ONIVYDE® regimen (NALIRIFOX) for 1L PDAC received sNDA approvals from the US FDA, Australia TGA, Taiwan FDA, and EU EMA and has been launched in Germany.

PIPELINE

New project R&D progress accelerated

1. Phase 1 clinical trial of PEP07 for hematologic cancers continues.
2. Phase 1 clinical trial of PEP07 for solid tumors began and the first patient dosed.
3. Multiple projects meet expectations with external AI/CADD collaboration.
4. R&D investment for new drugs continues to grow.

OPERATION

Operation with sustainable growth

1. 1H24 cash and cash equivalents and current financial assets (>3 months time deposits) at amortized cost: NT$3.88bn.
2. Kicked off the initial phase of scope 3 GHG inventory, scheduled to be completed before end of 2024.

1H 2024
OPERATIONAL OVERIVEW

Sales and Royalties Drive Long-term Growth

NT$(000)

Item / Year	2018	2019	2020	2021	2022	2023	1H 2024 YoY (%)
Taiwan Sales	87,384	180,389	214,828	235,469	277,594	278,547	135,033(-7%)
Royalties from Europe and Asia	109,825	133,651	271,584	419,366	376,789	426,652	230,562 (+22%)
Milestone/Sub-license Revenue	96,221	0	569,600	0	0	62,470	60,778 (N/A)
Total	293,430	314,040	1,056,012	654,835	654,383	767,669	426,373 (+28%)

1H 2024 Financial Results

NT$(000)	1H 2024	1H 2023	Amount Change	% Change
Operating revenue	426,373	334,403	91,970	28%
Operating costs	22,603	26,256	(3,653)	(14%)
Gross profit	403,770	308,147	95,623	31%
Sales expenses	15,789	19,770	(3,981)	(20%)
G&A expenses	46,864	46,935	(71)	--
R&D expenses	130,055	106,941	23,114	22%
Total operating expenses	192,708	173,646	19,062	11%
Operating income	211,062	134,501	76,561	57%
Total non-operating income and expenses	60,324	40,165	20,159	50%
Income before income tax	271,386	174,666	96,720	55%
Income tax expense	30,792	18,170	12,622	69%
Profit for the period	240,594	156,496	84,098	54%
EPS (NT$)	1.68	1.09	0.59	54%

ONIVYDE® STATUS & MARKET ANALYSIS

- ONIVYDE® regimen (NALIRIFOX) for 1L PDAC received sNDA from US FDA, Australia TGA, and Taiwan TFDA, and EU EMA and has been launched in Germany
- 2022 global patients with initial diagnose of pancreatic cancer: 510,991 (GLOBOCAN 2022 Data)
- 2021 Taiwan patients with initial diagnosis of pancreatic cancer: 3,190 (2021 Taiwan Cancer Registry Annual Report)

Development of Pancreatic Cancer Therapy in Taiwan



Taiwan PDAC Therapy Market Analysis



R&D PIPELINE

Pipeline Portfolio Focuses on Precision Oncology

Program		Indications	Lead	Preclinical	Phase I	Phase II	Phase III	Approval	Commercial Rights	Partner
ONIVYDE® (liposomal irinotecan)		2L PDAC						Approval	EU/Asia	IPSEN Innovation for patient care
		1L PDAC						Approval		
DNA Damage Response (DDR) & Precision Oncology	PEP07 (CHK1i)	Hematologic Cancers/Solid Tumors							Global	Sentinel ONCOLOGY
	PEP08	Undisclosed (Predictive Biomarker)							Global	PEI Owned
	PEP09	Undisclosed							Global	Undisclosed
	PEP10	Undisclosed (Predictive Biomarker)							Global	PEI Owned

A New Wave of Innovations within DNA Damage Response (DDR)



PEP07 Phase 1 Clinical Trials

Ph1b Mono

dose escalation/expansion in **hematologic cancers (first patient dosed in 2023/08)**

Ph1b Combo

dose finding/expansion in selected **hematologic cancers** e.g., **AML or MCL**

Ph1 Mono

dose escalation/expansion in advanced or metastatic **solid tumors (first patient dosed in 2024/04)**

Ph1b Combo

dose finding/expansion in selected **solid tumors**

Preclinical biomarker study is ongoing for further design of clinical trials.

Synthetic Lethality



Inhibition of Pathway A triggers compensatory Pathway B activation

Simultaneous inhibition of Pathway A and Pathway B is lethal for cancer cells

VISION FOR 2024

Vision for 2024

1. ONIVYDE® 1L PDAC sNDA certification obtained in US, AU, and Taiwan
2. ONIVYDE® 1L PDAC sNDA certification in EU (1H24)
3. PEP07 Phase 1 studies in hematologic cancers and solid tumors continue
4. One project in pipeline may reach IND ready stage (2H24)
5. Continue to advance pipeline progress toward preclinical stage
6. Complete initial scope 3 emissions data collection and analysis

THANK YOU

PharmaEngine, Inc.